Ascenta, Ascentage Pharma Group Corp., Debiopharm deal

Ascenta granted Debiopharm exclusive, worldwide rights to develop and commercialize AT-406 ( Debio 1143). Ascenta will complete two ongoing U.S. Phase I trials with the compound in acute myelogenous ...